Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients
Stockholm (ots/PRNewswire) - Oncopeptides AB, a company working to enhance oncology therapies, today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members of Oncopeptides' management ...